Valuation: Laboratorios Farmaceuticos Rovi, S.A.

Market Cap 3B 3.44B 2.84B 2.58B 4.82B 330B 4.84B 33.81B 13.07B 168B 12.94B 12.65B 537B P/E 2026 *
19.8x
P/E 2027 * 17.4x
Enterprise Value 2.99B 3.43B 2.83B 2.57B 4.8B 329B 4.83B 33.72B 13.04B 167B 12.9B 12.61B 535B EV / Sales 2026 *
3.86x
EV / Sales 2027 * 3.28x
Free-Float
31.63%
Yield 2026 *
1.66%
Yield 2027 * 1.98%
1 day+0.43%
1 week+1.83%
Current month-3.71%
1 month+1.12%
3 months-0.51%
6 months-26.94%
Current year-7.66%
1 week 57.3
Extreme 57.3
58.8
1 month 57.3
Extreme 57.3
61.8
Current year 53.15
Extreme 53.15
86.6
1 year 53.15
Extreme 53.15
86.6
3 years 45.82
Extreme 45.82
90.75
5 years 35.64
Extreme 35.64
90.75
10 years 35.64
Extreme 35.64
90.75
Manager TitleAgeSince
Chief Executive Officer - 27/07/2007
Director of Finance/CFO - 01/01/2001
Chief Operating Officer - -
Director TitleAgeSince
Chairman - 17/07/2021
Director/Board Member - 27/07/2007
Director/Board Member - 27/07/2007
Change 5-day change 1-year change 3-year change Capi.($)
+0.43%+1.83% - - 3.44B
+1.28%+2.62%+51.61%+100.19% 1,027B
+1.10%+1.45%+52.49%+67.37% 651B
+0.58%+3.54%+19.57%+73.56% 467B
+0.40%+5.35%+38.66%+40.57% 350B
+0.24%+3.95%+20.43%+26.56% 268B
+0.47%+6.90%+11.27%+16.67% 257B
+0.91%-0.70%+38.25%+45.67% 205B
+0.44%+1.57%-28.46%-56.83% 190B
+2.17%+4.20%+34.41%+99.41% 187B
Average +0.40%+2.49%+26.47%+45.91% 400.23B
Weighted average by Cap. -0.08%+2.62%+35.29%+62.16%

Financials

2026 *2027 *
Net sales 774M 889M 733M 666M 1.24B 85.11B 1.25B 8.73B 3.37B 43.25B 3.34B 3.26B 138B 892M 1.02B 845M 767M 1.43B 98.13B 1.44B 10.06B 3.89B 49.87B 3.85B 3.76B 160B
Net income 146M 168M 138M 126M 235M 16.08B 236M 1.65B 637M 8.17B 631M 617M 26.16B 173M 198M 164M 149M 278M 19.01B 279M 1.95B 754M 9.66B 746M 729M 30.93B
Net Debt -8.5M -9.76M -8.04M -7.31M -13.65M -935M -13.72M -95.81M -37.05M -475M -36.66M -35.84M -1.52B -72.51M -83.25M -68.62M -62.35M -116M -7.97B -117M -817M -316M -4.05B -313M -306M -12.97B
Logo Laboratorios Farmaceuticos Rovi, S.A.
Laboratorios Farmaceuticos Rovi, S.A. specializes in the research, development, manufacturing and marketing of biological medications and specialty drugs. Net sales break down by family of products as follows: - prescription pharmaceuticals (49%): intended for preventing and treating venous thrombo-embolic disease, post-menopausal osteoporosis, muscle pain, tooth and mouth infections, angina, osteoarthritis, etc.; - pharmaceutical products manufactured under contract (44%); - diagnostic products (7%): contrast products used in medical imaging with magnetic resonance, ultrasound, or X-rays. The group also offers hospital products and non-prescription pharmaceuticals. Net sales break down by source of revenue between sales of products (95.4%) and sales of services (4.6%). Net sales are distributed geographically as follows: Spain (77%), Italy (5%), Germany (3%), Portugal (2%), France (1%), Greece (1%) and other (11%).
Employees
2,470
Date Price Change
17/09/26 58.45 0.00%
16/09/26 €58.45 +1.39%
15/09/26 €57.65 -0.17%
14/09/26 €57.75 +0.09%
11/09/26 €57.70 +0.52%
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
58.65EUR
Average target price
74.36EUR
Spread / Average Target
+26.78%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!